Officials at x-ray manufacturer Del Global Technologies believe the company has added an important European dimension to its Valhalla, NY-based business by increasing its ownership in Villa Sistemi Medicali, an Italian radiographic/fluoroscopic firm.In
Officials at x-ray manufacturer Del Global Technologies believe the company has added an important European dimension to its Valhalla, NY-based business by increasing its ownership in Villa Sistemi Medicali, an Italian radiographic/fluoroscopic firm.
In January, Del Global obtained a 19% stake in Villa along with the nonrevocable option to increase its share to 80%.
In April, Del Global decided to exercise its option.
Villa Sistemi has annual sales of $20 million. Its line of radiographic/fluoroscopic systems and a line of portable imaging systems with power ratings up to 30 kW complements Del Globals existing line of products, said Leonard Trugman, Del Globals president.
Getting into the European imaging market has been one of Del Globals goals over the last five years, Trugman said. Before the Villa Sistemi acquisition, medical salessystems and subsystemsaccounted for 80% of Del Globals total sales (SCAN 2/2/00). The acquisition drives that to 90%.
Prior to 1990, Del Global manufactured mostly defense electronics.
The company shifted toward medical imaging in the early 1990s, primarily by acquiring companies that specialized in niche technologies Del Global lacked (SCAN 2/2/00).
Del Global purchased x-ray and mammography firm DynaRad in 1992, and in 1996 bought Gendex Medical from Dentsply International. In 1998, Del Global acquired Acoma Medical Imaging for $1.4 million. That year, the company posted the strongest fourth-quarter and fiscal-year results in its history. Year-end sales for 1998 were $62.3 million (SCAN 11/11/98).
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.